Analytical Data
-
Gene name
GRO-alpha/CXCL1
- Application
-
Alternative Names
NAP3; GRO1; GROa; GRO-A; MGSA-A; NAP3; SCYB1; Chemokine C-X-C-Motif Ligand 1; Melanoma Growth Stimulating Activity Alpha; Fibroblast Secretory Protein
-
Species
Rat
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 97% as determined by SDS-PAGE.
-
Uniprot
P14095
-
Expression Region
Ala25~Lys96
-
Protein Length
Partial
-
Molecular Weight
11.6kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
GRO-alpha, also known as CXCL1, is a CXC chemokine involved in the inflammatory response and plays a crucial role in the recruitment of neutrophils to sites of injury or infection. Research on GRO-alpha/CXCL1 has gained significant attention due to its involvement in various physiological and pathological processes, including cancer progression, wound healing, and immune responses. Elevated levels of GRO-alpha have been associated with tumor growth, angiogenesis, and metastasis, making it a potential biomarker for various cancers. Additionally, GRO-alpha is implicated in chronic inflammatory diseases, such as rheumatoid arthritis and chronic obstructive pulmonary disease (COPD), highlighting its relevance in understanding inflammation-induced tissue damage. The study of recombinant GRO-alpha protein has advanced our knowledge of its structure-function relationships and allowed for the exploration of its therapeutic applications, such as targeted cancer therapies and anti-inflammatory treatments. By utilizing recombinant technology, researchers can produce GRO-alpha in a controlled manner, facilitating the investigation of its biological activities and the development of inhibitors that modulate its function in pathological conditions. Overall, the comprehensive understanding of GRO-alpha/CXCL1's role in both health and disease underscores the importance of ongoing research in this area, paving the way for novel therapeutic strategies.
